Search 

Come and see us at booth #73

Selcia Limited is a leading worldwide provider of contract research services. Our headquarters are in Ongar, Essex and we have a branch in Hopkinton, MA. Selcia operates two divisions, Selcia Discovery, which provides integrated small molecule drug discovery to pharmaceutical and biotech clients, and Selcia Radiolabeling which specializes in 14C GMP radiolabelling.

In addition to general medicinal chemistry and biology capabilities applicable across a range of target classes, Selcia Discovery has particular strengths in three unique and highly synergistic technologies:
(1) medicinal chemistry of complex natural products
(2) capillary electrophoresis-based fragment and natural product screening
(3) PPI targets in particular peptidyl-prolyl isomerase targets (including cyclophilins, FKBPs, Pin1, together called PPIases).
Whilst relatively neglected by pharmaceutical companies in the past, understanding of the involvement of PPIases in many diseases is currently emerging. All PPIase inhibitors presently in clinical use or in development are natural products, natural product derivatives or have structures inspired by natural products.

The combination of these technologies has enabled Selcia to deliver several clinical PPIase inhibitors to clients, but has also generated IP for Selcia, which we have recently demerged into a new company, Mitopharm Limited who are in advanced license negotiations for a breakthrough drug in the field of acute and chronic neurodegenerative diseases. Other applications in the fields of chronic inflammatory diseases, oncology, COPD, and virus infections will be developed by Mitopharm either via investment or via joint R&D programs with pharmaceutical companies.

We have also recently established Selcia Pharma, a spin out company focussed on the optimisation/preclinical development and partnering of Selcia’s preclinical antimicrobial (antibacterial & antifungal) assets.

Come and see us at booth #73